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Abstract
Sodium nitroprusside (SNP) elicits various physiological effects, in part through generation of the membrane permeable
mediator nitric oxide (NO). In the heart, besides its role in regulating contractility, NO is involved in both protection from
and induction of cellular damage. The present study investigated the role of SNP in the regulation of the mitogen-activated
protein kinases (MAPKs) in isolated adult rat cardiomyocytes. SNP maximally activated Erk1, Erk2, p38 MAPK and
MAPKAPK2 in 5^10 min. The activation of MAPKAPK2 by SNP was blocked by the soluble guanylyl cyclase inhibitor,
1H-[1,2,4]oxadiazolol[4,3-a]quinoxalin-1-one (ODQ) and the p38 MAPK inhibitor, SB203580. The activation of Erk1 was
insensitive to ODQ but completely blocked by the Mek1 inhibitor PD98059. The membrane-permeable homologue of
cGMP, 8-Br-cGMP, also activated p38 MAPK (A0:5W50 WM) but not Erk1 and Erk2. These results indicate that p38
MAPK and MAPKAPK2 are activated by SNP in cGMP-dependent pathways, while the Erk1 activation by SNP is
independent of cGMP levels. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Sodium nitroprusside (SNP) is a commonly used
vasodilator which acts as a NO donor, targeting
many proteins either by directly binding heme-con-
taining proteins such as soluble guanylyl cyclase
(sGC), nitrosylation of thiol residues, nitration of
tyrosine or oxidizing DNA and proteins [1]. The ac-
tivation of sGC elevates cytosolic cGMP levels, by
converting GTP to cGMP, and results in the activa-
tion of cGMP-dependent protein kinase (PKG).
There are other known receptors for cGMP, which
include cGMP-stimulated phosphodiesterase, cGMP-
inhibited phosphodiesterase and cGMP-gated ion
channels [2^4]. Besides the vasodilating e¡ect of
SNP, it can also suppress proliferation of cells and
induces or inhibits apoptotic cell death in certain
cells [5^8], probably at least in part by regulating
mitogen-activated protein kinases (MAPKs) such as
extracellular signal-regulated kinases (Erk1 and
Erk2), p38 MAPK and c-Jun N-terminal kinase
(JNK) [7,9]. However, the signalling pathways lead-
ing to the activation of these MAPKs by NO are still
to be investigated.
In cultures of neonatal cardiomyocytes, SNP and
8-Br-cGMP induce apoptosis [10], whereas NO func-
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tions as either pro- or anti-apoptotic e¡ector in chick
embryonic heart cells [11]. NO is markedly produced
by ischemia followed by reperfusion [12], which may
in part result in either anti- or pro-apoptotic e¡ects
[13^15]. The regulation of MAPKs by SNP and 8-Br-
cGMP in cardiomyocytes has not yet been explored.
In the heart, activation of MAPKs has also been
implicated in many cardiac functions, such as cardiac
hypertrophy (reviewed in [16]), induction [17^19] or
inhibition [20] of apoptosis and ischemic precondi-
tioning [21]. The aim of this study was to delineate
the signalling pathways of SNP and 8-Br-cGMP in
the regulation of MAPKs in isolated cardiomyocytes
from rat hearts. In summary, this study showed that
SNP activated Erk1, Erk2, p38 MAPK and MAP-
KAPK2, a direct downstream substrate of p38
MAPK, but the stimulation of p38 MAPK and
MAPKAPK2 was achieved via cGMP-dependent
pathways, while the Erk1 and Erk2 activation was
mediated independently of cGMP.
2. Materials and methods
2.1. Materials
SNP and myelin basic protein (MBP) were ob-
tained form Sigma Chemical Co. (St. Louis, MO,
USA). ATF2 was purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). SB20350,
PD98059, 1H-[1,2,4]oxadiazolol[4,3-a]quinoxalin-1-
one (ODQ) and 8-Br-cGMP were bought from Cal-
biochem (San Diego, CA, USA). Rabbit polyclonal
antibodies for Erk1 and MAPKAPK2 were gener-
ated against the peptide sequences CGGPFTFDME-
LDDLPKERLKELIFQETARFQPGAPEAP (Erk1-
CT) and SRVLKEDKERWEDVKGC (Mapkapk2-
PCT). The p38 MAPK polyclonal antibody was
obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA) and phospho-speci¢c monoclonal
antibodies for Erks and p38 MAPK were pur-
chased from New England BioLabs (Beverly, MA,
USA).
2.2. Preparation of isolated cardiomyocytes
The isolation procedure was described previously
[22]. In brief, 50-day-old rat hearts were excised and
each heart was perfused in retrograde mode with
bu¡er A (Joklik minimal essential medium, contain-
ing 2 mM NaHCO3, 1.2 mM MgSO4 and 1 mM
DL-carnitine) for 5 min, followed by the same bu¡er
containing 25 WM Ca2 and 75 mU/ml of collagenase
(type II, Worthington) for 30 min at 37‡C. The soft-
ened ventricular tissue was then cut and teased to
small pieces with a scalpel, and incubated for
10 min in the same collagenase and Ca2 containing
bu¡er A with occasional agitation. The isolated ven-
tricular myocytes were settled for 10 min sequentially
in bu¡er A containing 50 WM, 100 WM, 500 WM and
1 mM Ca2, and at each step the supernatants were
discarded.
2.3. Treatment of isolated cardiomyocytes and protein
extraction
Isolated cardiomyocytes were stabilized in bu¡er A
containing 1 mM CaCl2 for 2 h and microscopically
checked for viability and cell number. The cell sus-
pension was then divided into aliquots of 0.8^1 mil-
lion viable cells and treated with various agents as
indicated in the ¢gure legends. Cells were pre-treated
with inhibitors for 30 min prior to the SNP treat-
ment. The reactions were stopped by freezing the
cells in liquid nitrogen after centrifuging the cell sus-
pension for 30 s at 100Ug and aspiration of the
supernatant. The frozen cell pellets were thawed in
1 ml of ice-cold homogenization bu¡er, containing
20 mM MOPS, 15 mM EGTA, 2 mM Na2EDTA,
1 mM Na3VO4, 1 mM dithiothreitol (DTT), 75 mM
L-glycerophosphate, 0.1 mM PMSF, 10 Wg/ml pep-
statin A, 1 Wg/ml aprotinin, 1 Wg/ml leupeptin and
1% Triton X-100, and sonicated at 4‡C with three
bursts of 30 s each. The resulting homogenate was
centrifuged at 100 000 rpm (240 000Ug) for 11 min in
a Beckman TLA-100.2 ultracentrifuge rotor, yielding
1^2 mg protein/ml.
2.4. Gel electrophoresis and immunoblotting
Extracts were added to SDS^PAGE sample bu¡er
(2.5% SDS, 10% glycerol, 50 mM HCl, pH 6.8, 0.5 M
L-mercaptoethanol and 0.01% bromophenol blue)
and boiled at 100‡C for 5 min. Electrophoresis was
performed with 11% SDS^PAGE gel as described
[23]. Proteins were electrophoretically transferred
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onto nitrocellulose membranes and Western blotting
was carried out [23].
2.5. Immunoprecipitation and determination of protein
kinase activities
Erk1, p38 MAPK and MAPKAPK2 were immu-
noprecipitated from 300 Wg of crude extracts follow-
ing incubation in 3% NETF (100 mM NaCl, 5 mM
EDTA, 50 mM Tris^HCl, pH 7.2, 50 mM NaF and
3% Nonidet P-40), 20 Wl of protein A-Sepharose
(previously blocked with 0.1% bovine serum albu-
min) and 1^10 Wg of antibodies for 3 h with constant
rotation at 4‡C. The protein A-Sepharose beads were
pelleted by centrifugation and washed in sequence
with 1 ml of 3% NETF, 0% NETF and reaction
bu¡er (25 mM L-glycerophosphate, 20 mM MOPS,
pH 7.2, 5 mM EGTA, 2 mM EDTA, 20 mM MgCl2,
1 mM Na3VO4, and 0.25 mM DTT). The beads were
then added to 30 Wl of reaction bu¡er containing a
substrate. For Erk1 and MAPKAPK2, 10 Wg of
MBP and heat shock protein 27 (hsp27) peptide
(RRLNRQLSVA), respectively, were used as sub-
strates. The reactions were started with the addition
of 50 WM [Q-32P]ATP (2000 cpm/pmol) and termi-
nated by spotting 15 Wl of the reaction mixtures
onto P81 phosphocellulose papers after 15 min at
30‡C. After washing the papers with 1% phosphoric
acid, they were counted in a scintillation counter.
The p38 MAPK activity was measured as above us-
ing ATF2 (10 Wg/assay) as a substrate. The reactions
were terminated by addition of 15 Wl of 5USDS
sample loading bu¡er [23]. The 32P-labelled sub-
strates resolved by SDS^PAGE were visualized by
autoradiography and the phosphotransferase activ-
ities were quanti¢ed by densitometric analysis.
2.6. Determination of protein concentration
Protein concentration was determined by Brad-
ford’s dye binding method, using the protein stan-
dard bovine serum albumin and procedures for the
micro-assay supplied by Bio-Rad Laboratories (Her-
cules, CA, USA).
3. Results
3.1. Activation of MAPKs by SNP
Isolated adult rat cardiomyocytes were treated
with SNP (100 WM) for di¡erent times indicated in
Fig. 1. The activations of Erk1 and Erk2 were ana-
lyzed using antibodies speci¢c to their phosphorylat-
ed and activated forms, and the phosphotransferase
activity of Erk1 toward MBP was measured after
speci¢c immunoprecipitation of the protein. SNP
stimulated the phosphorylation of both Erk1 and
Erk2 as early as 5 min and maximally within
10 min (Fig. 1B). Fig. 1A is a representative immu-
noblot, which shows that equal amounts of Erk1 and
Erk2 were analyzed for each of the time points. The
immunocomplexed phosphotransferase activity of
Erk1 re£ected its state of phosphorylation by immu-
noblotting. The phosphotransferase activity in-
creased as much as 70% in 5 min and maximally
Fig. 1. Activation of p44 and p42 Erks by SNP in isolated
adult cardiomyocytes. Isolated cardiomyocytes were treated
without and with SNP (100 WM) for up to 15 min. (A and B)
Representative Western blots of Erk1 and Erk2, and phospho-
Erk1 and phospho-Erk2, respectively. (C) Erk1 was speci¢cally
immunoprecipitated from cell extracts. (D) The phosphotrans-
ferase activity of the immunocomplexed Erk1 was measured,
using MBP as a substrate. To con¢rm the speci¢city of the im-
munoprecipitation experiments, immunoprecipitations were per-
formed in the absence of the antibodies (Ext) or cell extracts
(Abs). (D) Fold change in the activity of Erk1 (mean þ S.E.M.,
n = 5). *P6 0.05 vs. control.
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200^300% in 10 min (Fig. 1D). Fig. 1C shows a
representative immunoblot that indicates that Erk1
was speci¢cally immunoprecipitated and in compara-
ble amounts.
p38 MAPK and its immediate downstream kinase,
MAPKAPK2, are regulated di¡erentially from Erk1
and Erk2. As shown in Fig. 2A,B, p38 MAPK, based
on its state of phosphorylation detected immunolog-
ically, was also activated by SNP maximally by
10 min, which was slightly diminished in 15 min.
Consistent with the immunoblotting assay data, the
phosphotransferase activity of immunoprecipitated
p38 (Fig. 2C) toward ATF2 also increased maximally
by 10 min (Fig. 2D). MAPKAPK2 was also speci¢-
cally immunoprecipitated (Fig. 2E) and its phospho-
transferase activity toward heat shock protein (hsp)
peptide (PRLNRQLSVA) was measured (Fig. 2F). A
similar pattern of activation of MAPKAPK2 by SNP
was also observed, which showed maximal activation
at 5^10 min, and was reduced to the basal level in
15 min (Fig. 2F). These results clearly show that
SNP activated both the Erk1/Erk2 and p38 MAPK
signalling pathways.
3.2. Role of 8-Br-cGMP in the regulation of MAP
kinases
One of the well established targets of SNP and NO
is sGC, which converts GTP to cGMP [2^4]. To in-
vestigate the role of cGMP in the regulation of these
MAPKs, we treated isolated cardiomyocytes with a
membrane-permeable homologue of cGMP, 8-Br-
cGMP. As shown in Fig. 3, immunoblotting assays
using antibodies speci¢c for activated forms of
MAPKs indicated that p38 MAPK was activated
two-fold and maximally with 100 WM of 8-Br-
cGMP. Concentrations above 100 WM resulted in
reduced p38 MAPK phosphorylation (Fig. 3D). In
contrast, the phosphorylation states of Erk1 and
Fig. 2. Activation of p38 MAPK and MAPKAPK2 by SNP in
isolated cardiomyocytes. Isolated cardiomyocytes were treated
without and with SNP (100 WM) for up to 15 min. (A and B)
Representative Western blots of p38 MAPK and phospho-p38
MAPK, respectively. (C and E) p38 MAPK and MAPKAPK2
were speci¢cally immunoprecipitated from cell extracts and the
phosphotransferase activities of the immunocomplexed p38
MAPK and MAPKAPK2 were measured, using ATF2 and
hsp27 peptide (RRLNRQLSVA) as substrates. To con¢rm the
speci¢city of the immunoprecipitation experiments, immunopre-
cipitations were performed in the absence of the antibodies
(Ext) or cell extracts (Abs). (D) A representative autoradiogra-
phy of ATF2 phosphorylation. (F) Fold change in the activity
of MAPKAPK2 (mean þ S.E.M., n = 6). *P6 0.05 vs. control.
Fig. 3. Concentration-speci¢c regulation of p38 MAPK by
8-Br-cGMP. Phospho-speci¢c antibodies were used to recognize
the activation of Erk1 and Erk2 (A) and p38 MAPK (C). Pan-
els A and C show the same amount of proteins were loaded
onto each lane. (B and D) Representative phospho-speci¢c im-
munoblottings from three separate experiments.
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Erk2 were not changed with any concentrations of
8-Br-cGMP tested (Fig. 3B).
3.3. cGMP-dependent and -independent regulation of
Erk1 and MAPKAPK2 by SNP
Previous results showed that SNP activated both
Erk1, Erk2 and p38 MAPK, but cGMP only acti-
vated p38. To investigate whether the activations of
these MAPKs were mediated by cGMP signalling
pathways, we tested their activation in the presence
of various inhibitors or by other signalling molecules.
For these experiments, we assayed the phosphotrans-
ferase activities of the immunocomplexed Erk1, after
speci¢c immunoprecipitation as before. As shown in
Fig. 4A, SNP activated Erk1 but the activation was
not signi¢cantly in£uenced by pre-treatment with
20 WM ODQ, which is a sGC inhibitor. Further,
the treatment of 8-Br-cGMP (100 WM) failed to ac-
tivate Erk1 which was consistent to the activated
state-speci¢c immunoblotting assays as shown in
Fig. 3D. The activation of Erk1 by SNP was com-
pletely blocked by 10 WM PD98059, which is a Mek1
inhibitor (Fig. 4). Since 8-Br-cGMP may have stimu-
lated cGMP-inhibited or activated phosphodiester-
ases, resulting in changes of cAMP levels, we tested
whether cAMP could activate Erk1. Neither the ade-
nylate cyclase activator forskolin (20 WM for 10 min)
nor 8-chlorphenylthio-cAMP activated Erk1 (Fig.
4).
In contrast to Erk1, MAPKAPK2 activation by
SNP appeared to be diminished by pre-treatment of
20 WM ODQ. Consistent with the activated state-spe-
ci¢c immunoblotting assays toward p38 MAPK (Fig.
3B), direct treatment with 100 WM 8-Br-cGMP for
10 min was also able to activate MAPKAPK2 (up to
two-fold) (Fig. 4). The stimulation of MAPKAPK2
appeared to be mediated by p38 MAPK, since 25 WM
SB203580, a p38 MAPK inhibitor, abolished the
activation. Similar to Erk1, neither the adenylate
cyclase activator forskolin (20 WM for 10 min) nor
8-chlorphenylthio-cAMP (8-CPT-cAMP; 100 WM for
10 min) activated MAPKAPK2.
4. Discussion
Assignment of the physiological functions of SNP
and NO has been controversial. Depending on cell
types, SNP either induces or suppresses cell prolifer-
ation, in part by activating or inhibiting Erk1 and
Erk2, respectively [24,25,36]. In some cells, NO also
stimulates stress-activated MAPKs, such as p38
MAPK and c-Jun N-terminal kinase [9], but their
importance in cell proliferation is unknown. In neo-
natal cardiomyocytes, SNP, atrial natriuretic peptide
and 8-Br-cGMP induce apoptosis [10,26]. However,
the role of these MAPKs in the apoptosis has not yet
been described. In this study, we found that SNP
activated both Erk1 and Erk2, and p38 MAPK,
but only the activation of p38 was mediated by
cGMP in isolated adult cardiomyocytes. Whether
the activation of Erk1 and Erk2 by SNP was solely
dependent on the production of NO or other sub-
stances such as thiocyanide and cyanide has not been
addressed in this study. However, there have been no
reports describing the direct e¡ects of these substan-
ces in the regulation of MAPKs. Inhibition of Erk1
Fig. 4. cGMP-dependent and -independent regulation of
MAPKs by sodium nitroprusside. Isolated cardiomyocytes from
adult rats were treated with SNP (100 WM for 5 min), 8-Br-
cGMP (100 WM, for 10 min), forskolin (FSK; 20 WM for 10
min) and 8-CPT-cAMP (100 WM for 10 min). The inhibitors
ODQ (20 WM), PD98059 (20 WM) and SB203580 (25 WM) were
added 30 min before the treatment. Erk1 and MAPKAPK2
were speci¢cally immunoprecipitated from cell extracts and the
phosphotransferase activities of the immunocomplexed Erk1
and MAPKAPK2 were measured as in Figs. 1 and 2. Fold
stimulation of the phosphotransferase activity of Erk1 (mean þ
S.E.M., n = 5 for SNP, n = 3 for SNP+ODQ and n = 2 for
SNP+PD98059 (PD) ( þ range)). *P6 0.5 vs. control. NS: at
the 0.05 signi¢cance level, the means of the two groups were
not signi¢cantly di¡erent based on the paired t-test. The fold of
phosphotransferase activity of MAPKAPK2 was also similarly
plotted (mean þ S.E.M., n = 6 for SNP, n = 3 for SNP+ODQ
and n = 2 for SNP+SB20350 (SB) ( þ range)). #P6 0.05 vs. con-
trol. S: at the 0.05 signi¢cance level, the means of the two
groups were signi¢cantly di¡erent based on the paired t-test.
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and Erk2 by cGMP has, in fact, been observed in
baby hamster kidney cells, where PKG phosphory-
lates on the inhibitory Ser-43 of c-Raf [25]. Unlike
cGMP, cAMP activated neither Erk1 nor p38
MAPK in this study (Fig. 4). This observation is in
contrast to a previous report that showed that for-
skolin and dibutyryl cAMP activated Raf-1, and
Erk1 and Erk2 in neonatal cardiac cell culture [27].
However, the e¡ects of cAMP on the MAPK path-
ways are dependent on types of cells and suggested
to be to some extent dependent on the relative
amounts of Rap1, B-Raf and Raf-1 expressed by
the cell [28]. During postnatal development of rat
heart, the amount of Raf-1 expression is signi¢cantly
decreased [22]. Therefore, it may be possible that
changes in the levels of Raf-1 result in di¡erent ef-
fects. Di¡erential e¡ects in MAPK by cAMP during
development have also been observed in smooth
muscle cells, where a stimulation of cAMP levels
results in an increased DNA synthesis in neonatal
but not in adult cells [29].
The activation of p38 MAPK by 8-Br-cGMP is
not a unique observation in cardiomyocytes. In neu-
trophils, lipopolysaccharide activates p38 MAPK via
producing NO and cGMP, and 8-Br-cGMP itself is
able to activate p38 MAPK [30]. During cardiac is-
chemia and ischemia/reperfusion, NO production
peaks (more than 10-fold above the pre-ischemic lev-
el) in 40 s and diminishes in 15 min of reperfusion
[12]. The generation of NO, on the one hand, may
interact with superoxide, which results in the gener-
ation of peroxynitrite and causes cellular injury. On
the other hand, NO is involved in the post-ischemic
cardioprotection in biomechanical performances
which are independent of the endothelial functions
[31]. In addition, NO is implicated in triggering car-
dioprotective e¡ects occurring 24^76 h after brief
ischemia and reperfusion, which is known as delayed
ischemic preconditioning [32]. Altogether, NO is in-
volved in induction of cellular damage and apoptosis
as well as in the cardioprotection against ischemia.
These bimodal e¡ects of NO in the heart may be due
to its multiple cellular targets and its concentration-
speci¢c e¡ects. For example, NO and cGMP induced
a concentration-dependent biphasic contractile re-
sponse [33]. In the Jurkat human T-cells, SNP acti-
vated p38 MAPK which peaked at 300 WM and di-
minished at higher concentrations [9]. The dose-
dependent activation of p38 MAPK by 8-Br-cGMP
(Fig. 3B) may in part explain the multilateral e¡ects
of NO.
The physiological role and importance of p38
MAPK and MAPKAPK2 induced by NO and
8-Br-cGMP remains to be investigated but MAP-
KAPK2 can phosphorylate various transcription fac-
tors, such as CREB, ATF-1 and hsp27 [34]. Unphos-
phorylated hsp27 acts as an actin cap-binding
protein in the cell and inhibits polymerization of
F-actin ¢laments. The phosphorylation of hsp27 by
MAPKAPK2 appears to stimulate the polymeriza-
tion of actin, and this is thought to facilitate recovery
of actin micro¢lament networks, which are disrupted
during cellular stresses. Huot et al. [35] showed that
cells overexpressing hsp27 were more resistant to in-
jury from oxidative stress than cells overexpressing
hsp27 that lacked the phosphorylation site and fur-
ther demonstrated that the phosphorylation was spe-
ci¢cally mediated by the p38 MAPK and MAP-
KAPK2 pathway. Considering these observations,
the activation of MAPKAPK2 by brie£y surged
NO and cGMP production may play an important
role in the protection or preconditioning of the ische-
mic heart.
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